Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03804021 · ClinicalTrials.gov registry record
Long-Term Follow-up Study of ADVM-043
A clinical trial of Alpha-1 Antitrypsin Deficiency, sponsored by Adverum Biotechnologies.
- Completed
- Registry status
- 6
- Enrollment target
- 2
- Study locations
NCT03804021: Completed study of Alpha-1 Antitrypsin Deficiency, sponsored by Adverum Biotechnologies.
NCT03804021 is a study of Alpha-1 Antitrypsin Deficiency that has completed, run by Adverum Biotechnologies. The registered enrollment target is 6 participants, below the 2,342-participant average among 24 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03804021, a study of Alpha-1 Antitrypsin Deficiency, has completed, sponsored by Adverum Biotechnologies.
- COMPLETED
- Registry status
- 6 participants
- Enrollment target
- 2
- Study locations
Study Summary
ADVM-043-03 is a long-term follow-up (LTFU) study of subjects who participated in the ADVM-043-01 (NCT02168686) multi-center gene therapy clinical study (ADVANCE) that evaluated ADVM-043 for the treatment of Alpha-1 Antitrypsin (A1AT) deficiency.
Primary Outcome
All adverse events of special interest and all serious adverse events related to ADVM-043
Conditions Studied
Interventions
- GENETIC No Intervention
Study Locations (2)
Florida
- University of Florida - Gainesville
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-12-27 |
| Est. Completion | 2021-12-06 |
What the finished NCT03804021 record still lists
NCT03804021 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 2,342-participant average among 24 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Alpha-1 Antitrypsin Deficiency appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT03804021 reports a single indexed study location in Florida, South Carolina.
Frequently Asked Questions
What is clinical trial NCT03804021 about?
NCT03804021 is a clinical study titled "Long-Term Follow-up Study of ADVM-043". ADVM-043-03 is a long-term follow-up (LTFU) study of subjects who participated in the ADVM-043-01 (NCT02168686) multi-center gene therapy clinical study (ADVANCE) that evaluated ADVM-043 for the treatment of Alpha-1 Antitrypsin (A1AT) deficiency.
What is the current status of trial NCT03804021?
This trial is currently completed. The enrollment target is 6 participants. The study started on 2018-12-27. Estimated completion is 2021-12-06.
What conditions does trial NCT03804021 study?
This clinical trial studies the following conditions: Alpha-1 Antitrypsin Deficiency.
What interventions are being tested in trial NCT03804021?
The interventions under investigation include: No Intervention (GENETIC).
Who is sponsoring clinical trial NCT03804021?
This trial is sponsored by Adverum Biotechnologies, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03804021 being conducted?
This trial has 2 study locations across Florida, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alpha-1 Antitrypsin Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03804021's enrollment target sits among peer trials
6 25th of 24 the lowest of 24 other Alpha-1 Antitrypsin Deficiency trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alpha-1 Antitrypsin Deficiency trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
RECRUITING
-
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
RECRUITING
-
PiMZ Longitudinal Cohort (PiMZ Logic)
RECRUITING
-
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
RECRUITING · Phase 2
-
Gene Therapy for Alpha 1- Antitrypsin Deficiency
RECRUITING · Phase 1
-
Alpha-1 Research Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI